Navigation Links
Siemens Showcases Its Most Comprehensive and Advanced Breast Care Portfolio

Seek-Find-Act-Follow: Innovations Span Entire Breast Care Continuum, from Early Detection and Diagnosis, to Targeted Therapy, Monitoring and After


CHICAGO, Nov. 25 /PRNewswire-FirstCall/ -- Siemens Medical Solutions ( introduces the latest innovations to its breast care portfolio, designed to help detect, diagnose and treat breast cancer earlier, faster, and with greater precision, at the 93rd Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from Nov. 25 to 30 at McCormick Place (Booth #7713, Hall B). As the world's first full-service diagnostics company, Siemens is showcasing its unique capabilities to provide solutions that address each step of breast care.

(Logo: )

"Siemens continues to raise the bar for innovation by offering a comprehensive range of breast care solutions, as evidenced by the leading-edge technologies on display at this year's RSNA," said Erich R. Reinhardt, Ph.D., member of the Managing Board of Siemens AG and president and CEO of Siemens Medical Solutions. "Siemens is enabling facilities to provide quality care tailored to the individual patient's needs and optimize productivity, workflow, and, ultimately, financial performance."

By combining advanced imaging, laboratory diagnostics, and information technologies, Siemens helps physicians not only detect, diagnose and treat breast cancer in its earliest, most treatable stages, but also provides them with comprehensive after-care solutions. This holistic approach enables shorter exams, streamlined workflow, and improved patient outcomes. With the movement toward a multimodality approach to breast care, imaging technologies such as ultrasound and magnetic resonance imaging (MRI) are playing an increasing role in all stages of breast care. At RSNA, Siemens is showcasing its latest advancements in breast ultrasound and MRI, as well as the next generation of digital mammography systems and immunodiagnostic testing.

Digital Mammography Simplified: MAMMOMAT Novation S

Introducing MAMMOMAT(R) Novation S, a cost-effective solution for facilities that are making the transition to digital breast imaging but do not have the need for the advanced functionality of state-of-the-art systems. The MAMMOMAT Novation S optimizes workflow, utilizes the latest full-field amorphous Selenium (aSe) detectors and features Tungsten/Rhodium (W/Rh) X-ray technology, which reduces dose.

Ultrasound Technology Helping to Reduce Biopsies and Image Dense Breasts

Siemens' breakthrough breast ultrasound technology, eSie Touch(TM) elasticity imaging, has shown promise in reducing reliance on invasive breast biopsy procedures. According to published research as many as 80 percent of biopsied breast lesions are found to be benign. Elasticity imaging measures the mechanical properties of tissue providing additional information for enhanced diagnostic decision-making. Clinical studies indicate that elasticity imaging has the potential to increase specificity in the evaluation and determination of focal breast lesions. Elasticity imaging has recently been recognized as the "Best New Product of the Year" by the Stevie Awards for Women in Business -- an international competition recognizing the accomplishments of outstanding business women as well as products, services and innovations introduced to the marketplace by or for women.

In addition, the U-Systems SomoVu(TM) Automated Breast Ultrasound System* provides a fast, cost-effective, patient-friendly solution, especially when it comes to overcoming the challenges posed in imaging and screening of dense breast tissue. Unlike conventional ultrasound acquisition techniques where the user moves a transducer over the breast, automated breast scanning (ABS) technology is a single-sweep, automated acquisition technique that produces standardized, reproducible three-dimensional ultrasound images for improved diagnostic confidence.

Advances in MRI Breast Spectroscopy

A recent study published in Radiology found that proton MRI spectroscopy may eliminate 68 percent of biopsies for benign non-mass breast lesions found on standard MRI exams without missing any cancers++.

Siemens' solution for quantitative breast MRI breast spectroscopy, syngo(R) GRACE, allows physicians to obtain essential metabolic information about the biochemical composition of breast lesions. This additional information helps physicians better distinguish between malignant and benign lesions to potentially reduce the risk of unnecessary breast biopsies. Using choline as a biomarker, syngo GRACE provides improved differential diagnosis and enhanced confidence in therapy monitoring.

Advances in Immunodiagnostics

New advances in immunodiagnostics have led to the development of an in-vitro biomarker that may help physicians determine whether a metastatic breast cancer patient is responding to treatment. This biomarker, HER-2/neu, measures levels of human epidermal growth factor receptor-2, a protein that plays a pivotal role in the growth of some breast cancer cells. Siemens Medical Solutions Diagnostics' Serum HER-2/neu test is the first and only FDA-cleared blood test for measuring circulating levels of the HER-2/neu protein in the monitoring of patients with metastatic breast cancer. Over the course of disease, monitoring HER-2/neu levels yields important information about response to therapy, and may help physicians make more informed decisions when developing and modifying patient treatment regimens.

Molecular Imaging Technologies

Molecular imaging technologies play a central role in the characterization of masses found in the breast and have therefore had a major impact on the initial diagnosis, staging and follow-up care for breast cancer patients. Diagnostic SPECT-CT using Siemens Symbia TruePoint(TM) SPECT-CT imaging systems combines anatomical clarity obtained from CT with functional imaging using SPECT lymphoscintigraphy for accurate localization of sentinel nodes. This information is then used for biopsy to evaluate for nodal metastases.

The Biograph(TM) TruePoint PET.CT provides high quality images of 18F-FDG tracer, which shows a high sensitivity for the localization of distant metastases due to the high glucose affinity of proliferating tumor cells. This has made PET.CT a standard of care for breast cancer staging. Molecular imaging technologies can assist physicians in making more accurate assessments of indeterminate breast lumps, which can have an impact on therapeutic decisions.

* U-Systems, Inc. SomoVu(TM) Automated Breast Ultrasound System,

distributed by Siemens

++ Bartella L, et al "Enhancing Nonmass Lesions in the Breast: Evaluation

with Proton 1(H) MR Spectroscopy" Radiology 2007; 245: 80-87.

About Siemens Medical Solutions

Siemens Medical Solutions is one of the world's largest suppliers to the healthcare industry. The company is a renowned medical solutions provider with core competence and innovative strength in diagnostic and therapeutic technologies as well as in knowledge engineering, including information technology and system integration. With its laboratory diagnostics acquisitions, Siemens Medical Solutions will be the first fully integrated diagnostics company, bringing together imaging and lab diagnostics, therapy, and healthcare information technology solutions, supplemented by consulting and support services. The company delivers solutions across the entire continuum of care -- from prevention and early detection, to diagnosis, therapy and care. Siemens Medical Solutions employs more than 48,000 people worldwide and operates in 130 countries. In the fiscal year 2007 (until Sept. 30th), Siemens Medical Solutions reported sales of euro 9,85 billion, orders of euro 10,27 billion, and group profit of euro 1,32 billion (preliminary figures, unaudited). Further information can be found by visiting

SOURCE Siemens Medical Solutions
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
6. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
7. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
8. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
10. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
11. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and Markets ... "Advanced Wound Care Market by Type (Dressings, Therapy ... User (In-Patient Facility, Out-Patient Facility), and Geography - Global ... --> --> The ... definition and forecast of the global advanced wound care ...
(Date:11/26/2015)... PUNE, India , November 26, ... --> --> ... Research Report" and "Investigation Report on ... 2019 and 2021 forecasts data and ... library. . ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you ... for not only fulfilling the needs of advisers and clients but going above ... and providing top-tier customer service. However, there's always room for improvement, which is ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is ... Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College ... as only one of twelve colleges and universities in the state of California make ...
(Date:11/27/2015)... , ... November 27, 2015 , ... Dr. Thomas ... Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph ... that both STEMI and Sepsis conditions present in similar ways and require time-critical intervention ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer ... incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product ... Q-Suite 5.10 up-to-date with a version of Asterisk that will receive not only ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... Inevitably when ... Many customers choose to buy during the Black Friday and Cyber Monday ... don’t need to search the Internet high and low to find the best massage ...
Breaking Medicine News(10 mins):